Payment overview · 2025
General Payments
$101.91
2 reported records · 2 companies
Healthcare provider profile · identity verified
Austin James Williams, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MIDDLETOWN, OH · NPI 1346604774
Verified facts
What the public records show
CMS Open Payments records show Austin James Williams, M.D. received $101.91 in general payments during 2025 across 2 reported records.
Integra LifeSciences Corporation accounted for 84.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $85.57 | 84.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.34 | 16.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $101.91 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $85.57 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $85.57 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $85.57 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 477 | 144 |
| Gabapentin | Gabapentin | 309 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 76 |
| Lisinopril | Lisinopril | 220 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 73 |
| Omeprazole | Omeprazole | 198 | 61 |
| Metformin Hcl | Metformin Hcl | 189 | 54 |
| Ozempic | Semaglutide | 182 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 154 | 25 |
| Losartan Potassium | Losartan Potassium | 144 | 50 |
| Furosemide | Furosemide | 142 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 135 | 28 |
| Pregabalin | Pregabalin | 133 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 37 |
| Jardiance | Empagliflozin | 108 | 30 |
| Ibuprofen | Ibuprofen | 102 | 23 |
| Clonazepam | Clonazepam | 99 | 20 |
| Chlorthalidone | Chlorthalidone | 96 | 29 |
| Tramadol Hcl | Tramadol Hcl | 93 | 28 |
| Alprazolam | Alprazolam | 92 | 19 |
| Eliquis | Apixaban | 87 | 23 |
| Trazodone Hcl | Trazodone Hcl | 86 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 27 |
| Sertraline Hcl | Sertraline Hcl | 78 | 18 |
| Celecoxib | Celecoxib | 77 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 17 |
| Famotidine | Famotidine | 74 | 24 |
| Montelukast Sodium | Montelukast Sodium | 74 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 21 |
| Meloxicam | Meloxicam | 71 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 26 |
| Potassium Chloride | Potassium Chloride | 71 | 20 |
| Methocarbamol | Methocarbamol | 68 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 24 |
| Prednisone | Prednisone | 66 | 37 |
| Allopurinol | Allopurinol | 65 | 16 |
| Buspirone Hcl | Buspirone Hcl | 65 | 12 |
| Trulicity | Dulaglutide | 65 | 18 |
| Farxiga | Dapagliflozin Propanediol | 61 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 20 |
| Ondansetron Odt | Ondansetron | 53 | 14 |
| Lorazepam | Lorazepam | 52 | 12 |
| Simvastatin | Simvastatin | 50 | 15 |
| Spironolactone | Spironolactone | 50 | 16 |
| Baclofen | Baclofen | 49 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 17 |
| Carvedilol | Carvedilol | 44 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 16 |
| Metformin Hcl Er | Metformin Hcl | 43 | 15 |
| Ezetimibe | Ezetimibe | 42 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 34 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Mounjaro | Tirzepatide | 39 | 15 |
| Bupropion Xl | Bupropion Hcl | 38 | 15 |
| Fluconazole | Fluconazole | 38 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Sucralfate | Sucralfate | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 30 | 21 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 11 |
| Naproxen | Naproxen | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 29 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Azithromycin | Azithromycin | 26 | 24 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 11 |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 16 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | 12 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | 12 |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $101.91 · 2 records | Integra LifeSciences Corporation | Integra, Integra Dermal Regeneration Template, OTEZLA, PRIMATRIX, REPATHA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error